Shikimic acid protects against doxorubicin-induced cardiotoxicity in rats DOI Creative Commons

Maha Abdullah Alwaili,

Amal S. Abu-Almakarem,

Karim Samy El-Said

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 8, 2025

Abstract Doxorubicin (DOX) is used to treat a variety of malignancies; however, its cardiotoxicity limits effectiveness. Shikimic acid (SA) showed several promising biomedical applications. This study investigated the protective effect SA on DOX-induced in male rats. The ADMETlab 2.0 web server was predict pharmacokinetic properties SA. Molecular docking studies were conducted using AutoDock Vina. Fifty rats divided into 4 groups ( n = 10); G1 negative control; G2 injected with mg/kg DOX intraperitoneally (i.p.) once week for month; G3 gavaged by 1/10 LD 50 (280 mg/kg) daily month, and G4 as G3. After hematological, biochemical, molecular, histopathological investigations assessed. results that treatment led significant amelioration restoring inflammatory biomarkers, antioxidant gene expression, cardiac alterations. Importantly, impact against DOX-promoted deterioration targeting Nrf-2/Keap-1/HO-1/NQO-1 signaling pathway, which turn induces agents. These findings suggest could potentially mitigate toxicity during DOX-based chemotherapy.

Language: Английский

Shikimic acid protects against doxorubicin-induced cardiotoxicity in rats DOI Creative Commons

Maha Abdullah Alwaili,

Amal S. Abu-Almakarem,

Karim Samy El-Said

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 8, 2025

Abstract Doxorubicin (DOX) is used to treat a variety of malignancies; however, its cardiotoxicity limits effectiveness. Shikimic acid (SA) showed several promising biomedical applications. This study investigated the protective effect SA on DOX-induced in male rats. The ADMETlab 2.0 web server was predict pharmacokinetic properties SA. Molecular docking studies were conducted using AutoDock Vina. Fifty rats divided into 4 groups ( n = 10); G1 negative control; G2 injected with mg/kg DOX intraperitoneally (i.p.) once week for month; G3 gavaged by 1/10 LD 50 (280 mg/kg) daily month, and G4 as G3. After hematological, biochemical, molecular, histopathological investigations assessed. results that treatment led significant amelioration restoring inflammatory biomarkers, antioxidant gene expression, cardiac alterations. Importantly, impact against DOX-promoted deterioration targeting Nrf-2/Keap-1/HO-1/NQO-1 signaling pathway, which turn induces agents. These findings suggest could potentially mitigate toxicity during DOX-based chemotherapy.

Language: Английский

Citations

0